Etripamil
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications
Etripamil nasal spray (Cardamyst) for paroxysmal supraventricular tachycardia.
Journal: The Medical letter on drugs and therapeutics
Published: April 10, 2026
The present and future of antiarrhythmic drugs.
Journal: JRSM cardiovascular disease
Published: February 23, 2026
Minimal Blood Pressure Effects of Intranasal Etripamil for Paroxysmal Supraventricular Tachycardia.
Journal: JACC. Advances
Published: February 10, 2026
Advances in Antiarrhythmic Drug Therapy: Pharmacologic Management of Supraventricular Tachycardia.
Journal: Cardiac electrophysiology clinics
Published: January 29, 2026
Cardiovascular pharmacotherapy in 2025.
Journal: European heart journal. Cardiovascular pharmacotherapy
Published: December 18, 2025
Self-Administered Etripamil Nasal Spray Slows Ventricular Rate in Patients With Atrial Fibrillation: A Post Hoc Analysis of the NODE-303 Study.
Journal: Journal of cardiovascular electrophysiology
Published: October 09, 2025
Etripamil Nasal Spray to Keep the Doctor Away.
Journal: Journal of cardiovascular electrophysiology
Published: September 20, 2025
Methodological Considerations in the NODE-303 Trial of Etripamil for PSVT.
Journal: Journal of cardiovascular electrophysiology
Published: September 15, 2025
Landiolol (Rapiblyk), A Newly Approved, Ultra-Short Acting Intravenous β1-Adrenoreceptor Blocker for the Treatment of Supraventricular Arrhythmias.
Journal: Cardiology in review
Published: July 09, 2025
Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE-303 Open-Label Study.
Journal: Journal of cardiovascular electrophysiology
Published: April 30, 2025
Last Updated: 06/30/2026